- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 22.01. | Johnson & Johnson reports 9.1% increase in sales for Q4 2025 | ||
| 22.01. | Opna Bio's OPN-2853 secures FDA's orphan drug status for myelofibrosis | ||
| 21.01. | Davos26: Trump says tariff threats helped fix US drug pricing 'unfairness' | ||
| 21.01. | Pfizer and Novavax ink $530m vaccine delivery licensing deal | ||
| 21.01. | BMS and Microsoft partner for AI-based lung cancer detection | ||
| 21.01. | Novo Nordisk and Aspect Biosystems advance partnership for diabetes therapies | ||
| 20.01. | Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up | ||
| 20.01. | GSK scoops up RAPT Therapeutics for $2.2bn | ||
| 20.01. | DeepHow introduces PharmaCloud for pharmaceutical manufacturers | ||
| 20.01. | iRegene receives FDA RMAT designation for NouvNeu001 to treat Parkinson's | ||
| 19.01. | UK's pharma outlook buoyed by trans-Atlantic trade policies | ||
| 19.01. | Compounder sues Lilly and Novo for suppressing GLP-1RA competition | ||
| 19.01. | AstraZeneca to acquire China rights for AbelZeta's CAR-T therapy | ||
| 19.01. | FDA grants Novartis' ianalumab breakthrough therapy status for Sjögren's disease | ||
| 16.01. | FDA prevails over EMA in 2025 novel drug approvals | ||
| 16.01. | J&J's Caplyta doubles remission rate in MDD patients | ||
| 16.01. | UK's MHRA gives high-dose Wegovy the go-ahead in obesity | ||
| 16.01. | InterAx and Alveus collaborate on small-molecule metabolic treatment | ||
| 16.01. | Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal | ||
| 15.01. | JPM26: Fujifilm's modular manufacturing answer to pharma tariffs | ||
| 15.01. | JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success | ||
| 15.01. | Novo Nordisk Foundation pours $850m into European life sciences economy | ||
| 15.01. | JPM26: Jazz sells PRV for $200m, targets deals in 2026 | ||
| 15.01. | FDA and EMA release collaborative AI framework for drug development | ||
| 14.01. | JPM26: Regeneron will not overpay in M&A deals amid lead asset patent expiries |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.